Cart
sales@molnova.com
JAK
Janus kinases (JAKs) are cytoplasmic tyrosine kinases. They link cytokine signalling from membrane receptors to signal transducers and activators of transcription (STAT) transcription factors. Four JAK family members are known: JAK1, JAK2, JAK3 and TYK2. The JAK–STAT signalling paradigm was discovered two decades ago, providing a breakthrough in the understanding of cytokine biology . JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other.
Angiogenesis
JAK
-
JAK-STAT-IN-1
catalog no : M37203
cas no: 1236666-76-4
JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.
-
WDR5-IN-6
catalog no : M36914
cas no: 326901-92-2
WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus and is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.
-
Nimucitinib
catalog no : M36068
cas no: 2740557-24-6
Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.
-
Butyzamide
catalog no : M36057
cas no: 1110767-45-7
Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3.
-
Pumecitinib
catalog no : M35964
cas no: 2401057-12-1
Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.